Skip to main content
SpringerLink
Log in

Years of Potential Life Lost and Indirect Costs of Melanoma and Non-Melanoma Skin Cancer

A Systematic Review of the Literature

  • Review Article
  • Economic Burden of Skin Cancer
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Skin cancer is the most common form of cancer in the US, and an important public health concern both in the US and throughout the world. Given high incidence rates among young adults and the large number of deaths, skin cancer has the potential to result in significant years of potential life lost (YPLL) and lost productivity. The purpose of this study was to systematically review the published literature on the YPLL and the value of productivity loss from morbidity and premature mortality resulting from melanoma and non-melanoma skin cancer (NMSC).

Employing pre-defined search terms and inclusion/exclusion criteria, systematic searches were conducted in MEDLINE, EMBASE, CINAHL and Econlit. We selected studies that measured the societal burden of melanoma and NMSC — through estimating either the YPLL and/or the indirect costs.

We identified 16 relevant studies meeting our criteria, six were from the US and ten were from other industrialized countries; ten of the studies reported results on YPLL, eight on mortality costs and five on morbidity costs. Some studies reported results in more than one category.

From each eligible article and report, we extracted detailed information on the study population/country, study design, data analysis methods and study results. Data abstracted for each eligible study included estimated number of YPLL, YPLL per death and morbidity and mortality costs. The average number of YPLL per death was approximately 15 for melanoma and 10 for NMSC. We found the costs attributable to melanoma and NMSC ranged from $US39.2 million to $US28.9 million for morbidity and $US3.3 billion to $US1.0 billion for mortality, respectively.

It is clear from the published literature that skin cancer leads to significant YPLL and indirect costs associated with premature mortality and morbidity. Prevention and early detection efforts are important in helping reduce the incidence of melanoma and NMSC, and the related deaths and productivity losses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Table III

Similar content being viewed by others

References

  1. Centers for Disease Control and Prevention. Basic information about skin cancer [online]. Available from URL: http://www.cdc.gov/cancer/skin/basic_info/index.htm [Accessed 2010 Apr 28]

  2. US Cancer Statistics Working Group. United States cancer statistics: 1999–2006 incidence and mortality web-based report. Atlanta (GA): US Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute, 2010

    Google Scholar 

  3. Bleyer A, O’Leary M, Barr R, et al. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975–2000. Bethesda (MD): National Cancer Institute, 2006. NIH Pub. No. 06-5767

    Google Scholar 

  4. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002; 146 Suppl. 61: 1–6

    Article  PubMed  Google Scholar 

  5. Linos E, Swetter SM, Cockburn MG, et al. Increasing burden of melanoma in the United States. J Invest Dermatol 2009; 129 (7): 1666–74

    Article  PubMed  CAS  Google Scholar 

  6. de Vries E, Coebergh JW. Cutaneous maliginant melanoma in Europe. Eur J Cancer 2004; 40: 2355–66

    Article  PubMed  Google Scholar 

  7. Rigel DS. The effect of sunscreen on melanoma risk. Dermatol Clin 2002; 20: 601–6

    Article  PubMed  CAS  Google Scholar 

  8. Rigel DS. Trends in dermatology: melanoma incidence. Arch Dermatol 2010; 146 (3): 318

    Article  PubMed  Google Scholar 

  9. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol 1994; 30 (5 Pt 1): 774–8

    Article  PubMed  CAS  Google Scholar 

  10. Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 2010; 146 (3): 283–7

    Article  PubMed  Google Scholar 

  11. Cooper BS, Rice DP. The economic cost of illness revisited. Soc Secur Bull 1976; 39 (2): 21–36

    PubMed  CAS  Google Scholar 

  12. Haddix AC, Teutsch SM, Corso PS. Prevention effectiveness: a guide to decision analysis and economic evaluation. 2nd ed. New York: Oxford University Press, 2003

    Google Scholar 

  13. US Bureau of Labor and Statistics. Consumer price indexes. Washington, DC: Bureau of Labor Statistics, 2009 [online]. Available from URL: http://www.bls.gov/cpi [Accessed 2010 Jan 25]

    Google Scholar 

  14. Organization for Economic Co-operation and Development. Purchasing power parities (PPP). Paris: OECD [online]. Available from URL: http://www.oecd.org/department/0,3355,en_2649_34357_1_1_1_1_1,00.html [Accessed 2010 Nov 30]

  15. Albert VA, Koh HK, Geller AC, et al. Years of potential life lost: another indicator of the impact of cutaneous malignant melanoma on society. J Am Acad Dermatol 1990; 23 (2, pt 1): 308–10

    Article  PubMed  CAS  Google Scholar 

  16. Rainbolt T. Years of potential life lost: an evaluation of premature cancer deaths in Texas from 1981 through 1988. Tex Med 1992; 88 (1): 74–6

    PubMed  CAS  Google Scholar 

  17. Yabroff KR, Bradley CJ, Mariotto AB, et al. Estimates and projections of value of life lost from cancer deaths in the United States. J Natl Cancer Inst 2008; 100 (24): 1755–62

    Article  PubMed  Google Scholar 

  18. Burnet NG, Jefferies SJ, Benson RJ, et al. Years of life lost (YLL) from cancer is an important measure of population burden: and should be considered when allocating research funds. Br J Cancer 2005; 92 (2): 241–5

    PubMed  CAS  Google Scholar 

  19. Brochez L, Myny K, Bleyen L, et al. The melanoma burden in Belgium: premature morbidity and mortality make melanoma a considerable health problem. Melanoma Res 1999; 9 (6): 614–8

    Article  PubMed  CAS  Google Scholar 

  20. Osterlind A. Epidemiology on malignant melanoma in Europe. Acta Oncol 1992; 31 (8): 903–8

    Article  PubMed  CAS  Google Scholar 

  21. Nieto A, Ruiz-Ramos M, Abdel-Kader L, et al. Gender differences in rising trends in cutaneous malignant melanoma in Spain, 1975–98. Br J Dermatol 2003; 148 (1): 110–6

    Article  PubMed  CAS  Google Scholar 

  22. Sneyd M, Cox B. The control of melanoma in New Zealand. N Z Med J 2006; 119 (1242): U2169

    Google Scholar 

  23. O’Dea D. The costs of skin cancer toNew Zealand. Wellington: Wellington School of Medicine, University of Otago, 2000

    Google Scholar 

  24. O’Dea D. The costs of skin cancer toNew Zealand. Wellington: Wellington School of Medicine, University of Otago, 2009

    Google Scholar 

  25. Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc 1982; 60 (3): 429–62

    Article  PubMed  CAS  Google Scholar 

  26. Bickers DR, Lim HW, Margolis D, et al. The burden of skin diseases: 2004. A joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol 2006; 55 (3): 490–500

    Article  PubMed  Google Scholar 

  27. Kyle JW, Hammitt JK, Lim HW, et al. Economic evaluation of the US Environmental Protection Agency’s Sun Wise program: sun protection education for young children. Pediatrics 2008 May; 121 (5): e1074–84

    Article  Google Scholar 

  28. Morris S, Cox B, Bosanquet N. Cost of skin cancer in England. Eur J Health Econ 2009; 10 (3): 267–73

    Article  PubMed  CAS  Google Scholar 

  29. Nilsson GH, Carlsson L, Dal H, et al. Skin diseases caused by ultraviolet radiation: the cost of illness. Int J Technol Assess Health Care 2003; 19 (4): 724–30

    Article  PubMed  Google Scholar 

  30. Tinghog G, Carlsson P, Synnerstad I, et al. Societal cost of skin cancer in Sweden in 2005. Acta Derm Venereol 2008; 88 (5): 467–73

    Article  PubMed  Google Scholar 

  31. Bradley CJ, Yabroff KR, Dahman B, et al. Productivity costs of cancer mortality in the United States: 2000–2020. J Natl Cancer Inst 2008; 100 (24): 1763–70

    Article  PubMed  Google Scholar 

  32. Jemal A, Devesa SS, Hartge P, et al. Recent trends in cutabeous melanoma incidence among Whites in the United States. J Natl Cancer Inst 2001; 93 (9): 678–83

    Article  PubMed  CAS  Google Scholar 

  33. Cooke KR, Skegg DC, Fraser J. Trends in malignant melanoma of skin in New Zealand. Int J Cancer 1983; 31: 715–8

    Article  PubMed  CAS  Google Scholar 

  34. Sant M, Capocaccia R, Coleman MP, et al. Cancer survival increases in Europe, but international differences remain wide. Eur J Cancer 2001; 37: 1659–67

    Article  PubMed  CAS  Google Scholar 

  35. US Preventive Services Task Force. Screening for skin cancer. Rockville (MD): Agency for Healthcare Research and Quality, 2009

    Google Scholar 

  36. Australian Cancer NetworkMelanoma Guidelines Revision Working Party. Clinical practice guidelines for the management of melanoma in Australia and New Zealand. Wellington: Cancer Council Australia and Australian Cancer Network, Sydney and New Zealand Guidelines Group, 2008

    Google Scholar 

  37. Saraiya M, Glanz K, Briss P, et al. Interventions to prevent skin cancer by reducing exposure to ultraviolet radiation: a systematic review. Am J Prev Med 2004; 27 (5): 422–66

    PubMed  Google Scholar 

  38. Green AC, Williams GM, Logan V, et al. Reduced melanoma after regular sunscreen use: randomized trial followup. J Clin Oncol 2011 Jan 20; 29 (3): 257–63

    Article  PubMed  CAS  Google Scholar 

  39. Whitlock EP, Lin JS, Liles E, et al. Screening for colorectal cancer: a targeted, updated systematic review for the US Preventive Services Task Force. Ann Intern Med 2008; 149 (9): 638–58

    PubMed  Google Scholar 

  40. Mandelblatt JS, Cronin KA, Bailey S, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med 2009; 151 (10): 738–47

    PubMed  Google Scholar 

  41. US Preventive Services Task Force. Screening for cervical cancer. Rockville (MD): Agency for Healthcare Research and Quality, 2003

    Google Scholar 

  42. Ekwueme DU, Strebel PM, Hadler SC, et al. Economic evaluation of use of diphtheria, tetanus, and acellular pertussis vaccine or diphtheria, tetanus, and whole-cell pertussis vaccine in the United States, 1997. Arch Pediatr Adolesc Med 2000; 154 (8): 797–803

    PubMed  CAS  Google Scholar 

  43. Zhou F, Santoli J, Messonnier ML, et al. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001. Arch Pediatr Adolesc Med 2005; 159 (12): 1136–44

    Article  PubMed  Google Scholar 

  44. Carter R, Marks R, Hill D. Could a national skin cancer primary prevention campaign in Australia be worthwhile? An economic perspective. Health Promot Int 1999; 14 (1): 73–82

    Article  Google Scholar 

  45. Shih S, Carter R, Sinclair C, et al. Economic evaluation of skin cancer prevention in Australia. Prev Med 2009; 49 (5): 449–53

    Article  PubMed  Google Scholar 

  46. Hodgson TA. The state of the art of cost-of-illness estimates. Adv Health Econ Health Serv Res 1983; 4: 129–64

    PubMed  CAS  Google Scholar 

  47. Drummond M. Cost-of-illness studies: a major headache? Pharmacoeconomics 1992; 2 (1): 1–4

    Article  PubMed  CAS  Google Scholar 

  48. Cockburn M, Swetter S, Peng D, et al. Melanoma underreporting: why does it happen, how big is the problem, and how do we fix it? J Am Acad Dermatol 2008; 59 (6): 1081–5

    Article  PubMed  Google Scholar 

  49. Brown ML, Riley GF, Schussler N, et al. Estimating health care costs related to cancer treatment from SEER Medicare data. Med Care 2002; 40 (8 Suppl.): IV-104–17

    Google Scholar 

  50. Bataille V, de Vries E. Melanoma — part 1: epidemiology, risk factors, and prevention. BMJ 2008; 337: a2249

    Article  Google Scholar 

  51. Armstrong B, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B 2001; 63 (1-3): 8–18

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to conduct this study or prepare this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this review.

Gery P. Guy Jr, PhD, MPH, was supported in part by the Research Participation Program at the Centers for Disease Control and Prevention (CDC) administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and CDC.

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of CDC.

Author information

Authors and Affiliations

  1. Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, CDC, 4770 Buford Highway, Atlanta, GA, 30341, USA

    Gery P. Guy Jr &  Donatus U. Ekwueme

Authors
  1. Gery P. Guy Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Donatus U. Ekwueme
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Donatus U. Ekwueme.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guy, G.P., Ekwueme, D.U. Years of Potential Life Lost and Indirect Costs of Melanoma and Non-Melanoma Skin Cancer. Pharmacoeconomics 29, 863–874 (2011). https://doi.org/10.2165/11589300-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11589300-000000000-00000

Keywords

Search

Navigation